Antibe Therapeutics Inc.
ATBPF
$0.2156
$0.025613.47%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -13.76M | -13.84M | -14.77M | -14.80M | -16.31M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -78.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.09M | 1.42M | 2.10M | 2.38M | 2.53M |
| Change in Net Operating Assets | -868.40K | -944.40K | 470.70K | 44.60K | 1.01M |
| Cash from Operations | -13.54M | -13.37M | -12.20M | -12.38M | -12.85M |
| Capital Expenditure | 1.50K | -6.60K | -6.60K | -6.60K | -8.90K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | 0.00 |
| Divestitures | 465.80K | 234.40K | 234.40K | 234.40K | 411.80K |
| Other Investing Activities | 13.50M | 6.02M | 4.56M | -9.49M | -25.03M |
| Cash from Investing | 13.97M | 6.24M | 4.79M | -9.26M | -24.63M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.00K | -1.00K | -40.00K | -79.00K | -117.00K |
| Issuance of Common Stock | -- | -- | -- | -- | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 160.00K | 159.00K | 159.00K | 159.00K | -1.00K |
| Cash from Financing | 117.60K | 116.90K | 87.00K | 56.40K | -92.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 549.30K | -7.00M | -7.33M | -21.58M | -37.57M |
